Screening and Docking Molecular Studies of Natural Products Targeting overexpressed Receptors HER-2 in Breast Cancer.

Breast cancer is the first cancer to affect a community. Because of its extremely high mitotic activity, breast cancer that tests positive for HER 2 is considered to have a poor prognosis. Due to the side effects of chemical drugs, patients are increasingly turning to natural medicine, such as phytotherapy and nutritherapy. The study uses a bioinformatics approach (molecular docking) to searchfor new, non-toxic anti-cancer inhibitors. The studyscreens 102 ligands from natural and dietary compounds that are likely to interact with the HER-2. The virtual screening results of the allow us to select the 23 best compounds which can be proposed as the most effective HER-2 inhibitors. Lycopene would be a very promising ligand which presents a DeltaG of -9.82 kcal/mol. Other promising ligands include beta-carotene (DeltaG of -8.58), P-cumaric acid kcal/mol (DeltaG of -8.57) and Curcumin (DeltaG of -8.46). Other compounds, luteolin, anacardium (Anacardic acid) ,and alpha-Tocopherol, were found to have the strongest inhibitory effects with DeltaG values of -7.92 kcal/mol, -7.89 kcal/mol, and-7.85 kcal/mol, respectively. These compounds act directly on residues keys found in the hydrophobic pocket II (ATP binding site) and the hydrophobic region (the αC-β4 loop) of the EGFR domain. Pinoresinol, Kaempferol and Caffeic acid have DeltaGs of -7.48 Kcal/mol, -6.88 Kcal/mol and -6.34 kcal/mol, respectively. These three ligands are specific to the conserved regions of the HER-2 receptor and interact with the C-terminal, the C-lobe activation loop and the N-lobe P loop of the tyrosine kinase domain, respectively. Lapatinib (chemical compound) and quercetin (natural compound) have DeltaG of -7.58 kcal/mol and -7.28 kcal/mol, respectively, form a hydrogen bond with the same residue in the hydrophobic region. All the natural molecules seem very promising and, after <i>in vitro</i>/<i>in vivo</i> tests, could constitute good substitutes for the chemotherapies which are currently used to treat breast cancers as well as other cancers.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2025-06-01
DOI
https://doi.org/10.32592/ari.2025.80.3.651
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Screening and Docking Molecular Studies of Natural Products Targeting overexpressed Receptors HER-2 in Breast Cancer.

Maouche Naima, Khemili-Talbi Souad, Lenchi Nesrine
PubMed
HER2/EGFR in Cancer Research
article

Screening and Docking Molecular Studies of Natural Products Targeting overexpressed Receptors HER-2 in Breast Cancer.

Maouche Naima, Khemili-Talbi Souad, Lenchi Nesrine
article en

Abstract

Breast cancer is the first cancer to affect a community. Because of its extremely high mitotic activity, breast cancer that tests positive for HER 2 is considered to have a poor prognosis. Due to the side effects of chemical drugs, patients are increasingly turning to natural medicine, such as phytotherapy and nutritherapy. The study uses a bioinformatics approach (molecular docking) to searchfor new, non-toxic anti-cancer inhibitors. The studyscreens 102 ligands from natural and dietary compounds that are likely to interact with the HER-2. The virtual screening results of the allow us to select the 23 best compounds which can be proposed as the most effective HER-2 inhibitors. Lycopene would be a very promising ligand which presents a DeltaG of -9.82 kcal/mol. Other promising ligands include beta-carotene (DeltaG of -8.58), P-cumaric acid kcal/mol (DeltaG of -8.57) and Curcumin (DeltaG of -8.46). Other compounds, luteolin, anacardium (Anacardic acid) ,and alpha-Tocopherol, were found to have the strongest inhibitory effects with DeltaG values of -7.92 kcal/mol, -7.89 kcal/mol, and-7.85 kcal/mol, respectively. These compounds act directly on residues keys found in the hydrophobic pocket II (ATP binding site) and the hydrophobic region (the αC-β4 loop) of the EGFR domain. Pinoresinol, Kaempferol and Caffeic acid have DeltaGs of -7.48 Kcal/mol, -6.88 Kcal/mol and -6.34 kcal/mol, respectively. These three ligands are specific to the conserved regions of the HER-2 receptor and interact with the C-terminal, the C-lobe activation loop and the N-lobe P loop of the tyrosine kinase domain, respectively. Lapatinib (chemical compound) and quercetin (natural compound) have DeltaG of -7.58 kcal/mol and -7.28 kcal/mol, respectively, form a hydrogen bond with the same residue in the hydrophobic region. All the natural molecules seem very promising and, after <i>in vitro</i>/<i>in vivo</i> tests, could constitute good substitutes for the chemotherapies which are currently used to treat breast cancers as well as other cancers.

PubMedVol. 80(3)
University of Algiers Benyoucef Benkhedda (DZ), University of Boumerdes (DZ)
Zero hunger
Openalex Percentile: Top 27%
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.